Top 17 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

Creator: OneDayMD Editorial Team
Published: 2023-07-01

Top 17 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

October 19, 2026

Medically reviewed by Dr. Frank Yap, MD | Written by OneDayMD Editorial Team | Last updated October 2026

Quick Answer

Of the 17 supplements reviewed here, the deepest human evidence supports vitamin D3 (with K2 and magnesium), polysaccharide-K (PSK) from turkey tail as an add-on to chemotherapy in Japanese trials, berberine for preventing colorectal adenoma recurrence, omega-3 fatty acids, curcumin and green tea EGCG. Even these show mixed rather than uniformly positive results. Melatonin looked promising in small trials, but the largest randomized trial found no benefit in early-stage lung cancer. A few supplements, namely high-dose beta-carotene, vitamin E and long-term high-dose B6/B12, have been linked to higher cancer risk in specific groups. No supplement replaces conventional cancer treatment, and antioxidant pills are generally discouraged during chemotherapy or radiotherapy unless your oncologist directs otherwise. This is educational information, not personal medical advice.

What changed in the October 2026 update

Expanded from a Top 10 to a Top 17. The seven supplements that were previously grouped under “Others” now have full entries, and the list is re-ranked by strength of human evidence.
Corrected the aged garlic extract trial description (the 52% figure belongs to H. pylori treatment, not garlic).
Corrected the SUNSHINE vitamin D dosing, added the VITAL trial, and flagged DO-HEALTH’s cancer result as an exploratory endpoint.
Clarified that the EGCG response-rate figures come from a single-arm trial and a small randomized phase II study, and re-tiered the green tea breast cancer recurrence data as observational.
Clarified that berberine’s 6-year data is a retrospective follow-up of a 2-year randomized trial.
Added PSK meta-analysis data, new safety notes, a 17-row summary table, expanded FAQ with schema, and an AI-assistant section.

How to Read the Evidence
The 17 at a Glance (Summary Table)
Should You Take Supplements During Cancer Treatment?

Vitamin D3 and K2 (with Magnesium)
Turkey Tail Mushroom (PSK and PSP)
Berberine
Omega-3 Fatty Acids (Fish Oil)
Turmeric (Curcumin)
Green Tea (EGCG)
Aged Garlic Extract
Korean Red Ginseng
Melatonin
Vitamin C and Quercetin
Magnesium and Molecular Hydrogen
Selenium
Sulforaphane
Probiotics and the Microbiome
Beta-Glucans (Medicinal Mushrooms)
Creatine
Thiamine (Vitamin B1)

Supplements That May Increase Cancer Risk
Why Antioxidants Need Caution During Treatment
Nicotinamide Riboside: A Cautionary Note
Conclusion and Key Takeaways
Frequently Asked Questions
Ask an AI About This Guide

Searching for straight answers on cancer, diet and supplements is frustrating. Marketing claims run far ahead of the science, and it is hard to tell which recommendations rest on randomized trials and which rest on a testimonial and a sales page.

“Anti-cancer supplement” is itself a misleading phrase. A nutrient can be protective in one setting, such as correcting a real deficiency, and neutral or harmful in another, such as mega-dosing during chemotherapy. This guide walks through the 17 supplements with the most published research, ranks them by the strength of the human evidence, and flags the ones associated with higher cancer risk.

How to Read the Evidence

Each supplement carries an evidence-tier badge based on the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy. Ranking reflects the strength and consistency of human evidence for a cancer-relevant outcome, then clinical relevance.

Tier	What it means
Level 1	Systematic review or meta-analysis of multiple randomized controlled trials (RCTs)
Level 2	A single RCT, or a few RCTs with mixed results
Level 3	Cohort or case-control studies (observational, no randomization)
Level 4	Case series, case reports, or very early human studies (hypothesis-generating)
Level 5	Preclinical: animal models, cell culture, or mechanistic and expert opinion

A cell-culture finding is a starting point, not proof that something works in a living person. A Level 5 supplement is not necessarily useless; it is simply unproven in humans so far.

The 17 at a Glance

#	Supplement	Best tier	Strongest human signal	Key caveat
1	Vitamin D3 + K2	Level 1	Possible lower cancer mortality with daily dosing	Large VITAL trial did not cut overall incidence; K2 interacts with warfarin
2	Turkey tail (PSK/PSP)	Level 1	Better survival when added to chemo (colorectal, gastric)	Japanese trials with older regimens; OTC products vary
3	Berberine	Level 2	Fewer colorectal adenoma recurrences after polypectomy	Surrogate endpoint; China-based trial program
4	Omega-3	Level 2	Benefit seen in combination (DO-HEALTH)	VITAL found no incidence benefit; chemo interaction question
5	Curcumin	Level 2	Signals across several cancers in small RCTs	Poor absorption; evidence thin and varied
6	Green tea EGCG	Level 2-3	Lower breast cancer recurrence in observational data	Inconsistent overall; high-dose extracts can harm the liver
7	Aged garlic extract	Level 2	Lower gastric cancer mortality at 22 years	Single trial, high-risk population; no incidence benefit
8	Korean red ginseng	Level 2-3	Less cancer-related fatigue; lower pooled risk (observational)	Interactions with anticoagulants and diabetes drugs
9	Melatonin	Level 2	Older small trials positive	Largest RCT (AMPLCaRe) found no benefit overall
10	Vitamin C + quercetin	Level 2-4	IV route under study as chemo adjunct	Oral and IV behave very differently
11	Magnesium + molecular hydrogen	Level 3 / 4-5	Higher magnesium intake linked to lower colorectal risk	Observational; hydrogen data very early
12	Selenium	Level 3	Lower pancreatic cancer risk at high toenail levels	Trial evidence null; narrow safety window
13	Sulforaphane	Level 4-5	Early prostate cancer trial	Mostly preclinical
14	Probiotics / microbiome	Level 4-5	Gut bacteria influence immunotherapy response	No validated protocol; some data suggest harm
15	Beta-glucans	Level 5	Immune activation in lab studies	Little cancer outcome data in humans
16	Creatine	Level 5	Dendritic-cell effects in a 2026 lab study	No clinical cancer data yet
17	Thiamine (B1)	Level 4	Corrects chemo-related deficiency	Supportive care, not anti-cancer; high doses debated

Should You Take Supplements During Cancer Treatment?

Dietary supplements are regulated far more loosely than medicines. In the United States the FDA does not review them for safety or efficacy before sale, and manufacturing quality varies widely between brands.

NCCN guidance calls for screening and correcting true deficiencies, most commonly vitamin D, B12 and folate, in patients at risk, particularly those on hormone-deprivation therapy or with bone metastases. The usual serum 25-hydroxyvitamin D target is roughly 30–50 ng/mL. Oncology specialists caution against “just in case” high-dose supplementation, since over-supplementation carries its own risks, including liver toxicity, drug interactions and reduced treatment efficacy. A 2024 review in Cancers made the less-discussed point that several common supplements have been associated with increased cancer risk in specific populations.

Bottom line: before starting any supplement, especially during active treatment, talk to your oncologist or pharmacist. Several supplements below interact with chemotherapy, radiotherapy, blood thinners and other medicines.

1. Vitamin D3 and K2 (with Magnesium)

Level 1 — Meta-analyses of RCTs, results mixed

Vitamin D has one of the deepest evidence bases on this list. A 2025 analysis in Nutrients pooled 50 studies with more than 1.3 million participants and found a consistent inverse relationship between vitamin D status and colorectal cancer risk, though that is observational data.

Trial results are less clear-cut:

A 2023 meta-analysis of 14 RCTs (Kuznia et al., Ageing Research Reviews) found a 6% reduction in cancer mortality that was not statistically significant overall, but rose to a significant 12% when restricted to trials using daily rather than large periodic doses.
The large VITAL trial (about 25,000 adults, 2,000 IU/day) did not reduce overall cancer incidence in its primary analysis. A secondary analysis suggested fewer advanced (metastatic or fatal) cancers, concentrated in people of normal body weight.
The DO-HEALTH trial (2,157 adults aged 70+) reported a 61% lower risk of invasive cancer with daily vitamin D3 (2,000 IU), marine omega-3s (1 g) and a home strength program combined. Cancer was an exploratory endpoint with only 81 cases, and the individual components did not reach significance alone, so treat it as a promising signal rather than proof.
In the phase II SUNSHINE trial, higher-dose vitamin D3 (8,000 IU/day for two weeks, then 4,000 IU/day) added to chemotherapy in metastatic colorectal cancer was associated with longer progression-free survival than standard-dose (400 IU/day). It was a small phase II study and needs confirmation.
The Women’s Health Initiative found no reduction in colorectal cancer with vitamin D plus calcium over seven years, although the dose (400 IU/day) was low and many participants supplemented on their own.

What level should you target?

NCCN guidance supports correcting deficiency toward roughly 30–50 ng/mL, taken with a fat-containing meal. Some integrative practitioners aim for 50–70 ng/mL based on prevention data, but that is a different goal from treating a clinical deficiency, and any target above the standard range should be discussed with your physician with periodic blood tests. Toxicity is uncommon but real at very high sustained doses.

Vitamin K2 and magnesium

K2: a large German cohort (EPIC-Heidelberg, over 24,000 adults) linked higher dietary K2 intake with lower cancer incidence and mortality, with the clearest signals for lung and prostate cancer. This is observational. K2 can interact with warfarin and other blood thinners.

Magnesium: it is a required cofactor for activating vitamin D, and high-dose vitamin D can deplete magnesium. A randomized trial in the American Journal of Clinical Nutrition found magnesium acted more like a regulator than a booster, raising vitamin D in people who started low and lowering it in those who started high. Some clinicians pair about 500 mg magnesium with D3/K2; individualize this, especially with kidney disease.

Vitamin K2 and Warfarin (Caution)

Important safety note: Vitamin K can interact significantly with warfarin (Coumadin®), an anticoagulant (blood thinner). If you take warfarin, keep your vitamin K intake from foods and supplements consistent from day to day. Sudden increases or decreases in vitamin K intake can alter warfarin’s effect, potentially increasing the risk of blood clots or bleeding, respectively. Consult your doctor or pharmacist before starting, stopping, or changing vitamin K supplements. If you are considering a vitamin D3 + K2 supplement, seek medical advice first, as vitamin K2 can affect warfarin treatment. Do not stop or change your warfarin dose without medical guidance.

Buying guide: Vitamin D3 + K2 (The Wellness Company)

2. Turkey Tail Mushroom (PSK and PSP)

Level 1 — for purified PSK with chemotherapy; OTC extracts Level 4-5

Trametes versicolor yields two well-studied polysaccharide extracts, PSK (Krestin) and PSP, used as adjuvant biological response modifiers in East Asia for decades. This is where the strongest survival-type evidence in this article sits:

A meta-analysis of three centrally randomized trials (1,094 patients with curatively resected colorectal cancer) found chemotherapy plus PSK improved overall survival (risk ratio 0.71) and disease-free survival (0.72) versus chemotherapy alone.
A meta-analysis of eight randomized trials (8,009 patients) concluded adjuvant PSK improves survival after curative gastric cancer resection.
A 2017 network meta-analysis of 23 trials (10,684 patients) found PSK combined with chemotherapy significantly improved 3- and 5-year overall survival in gastrointestinal cancers.

Important caveats: most of these trials were run in Japan, often decades ago, with older chemotherapy regimens. PSK has not been tested against modern regimens or immunotherapy. PSK is approved in Japan as an adjunct to cancer therapy but is not approved by the FDA or EMA for cancer treatment. In the U.S., turkey tail products are sold as dietary supplements without cancer claims, and over-the-counter products are not standardized to PSK or PSP content, so the trial results should not be assumed to transfer to any given bottle.

Buying guide: SHIELD formula (The Wellness Company)

3. Berberine

Level 2 — RCT plus retrospective extended follow-up

Berberine is a plant alkaloid from barberry and tree turmeric with a long history of use for metabolic conditions. It activates AMP-activated protein kinase (AMPK), similar to metformin, which has itself drawn interest in cancer research.

The key study is a randomized, double-blind, placebo-controlled trial (CBAR, 891 patients, Lancet Gastroenterology & Hepatology 2020) in which berberine after colorectal polyp removal reduced adenoma recurrence over two years (about 36% vs 47%). A 6-year follow-up in Cell Reports Medicine (2025) reported lower adenoma recurrence (34.7% vs 52.1%) and fewer new neoplasms (63.4% vs 71.0%). Note that this follow-up was a retrospective cohort extension of the original two-year randomized trial, not a new randomized trial, and not every participant could be followed.

An April 2026 review described berberine as a multifunctional chemotherapy adjuvant, noting gastrointestinal tolerability as its main practical limit and nano-delivery formulations in development. Adenoma recurrence is a surrogate endpoint; no trial has shown fewer colorectal cancer deaths. Oral bioavailability is poor. Berberine can interact with medicines processed by the liver, and it is not recommended in pregnancy.

Buying guide: Berberine formulated for absorption (Amazon)

4. Omega-3 Fatty Acids (Fish Oil)

Level 2 — RCTs, mixed; mostly combination interventions

More than 3,000 PubMed-indexed studies have examined omega-3s and cancer, but the randomized picture is mixed. The VITAL trial found 1 g/day of marine omega-3s did not reduce overall cancer incidence. The DO-HEALTH combination result described above (vitamin D3 + omega-3 + exercise) is notable but cannot isolate omega-3’s own contribution. The 2024 CAPFISH-3 RCT found that a high-omega-3, low-omega-6 diet plus fish oil for one year reduced the Ki-67 proliferation marker in prostate cancer. In mouse models, omega-3s enhanced the tumor-fighting effect of immunotherapy, which has not been confirmed in humans.

Cautions: a 2015 mouse study raised the possibility that fish oil could blunt chemotherapy in some contexts, which is why some integrative clinicians suggest ground flaxseed instead during chemotherapy. That substitution is untested head-to-head and should be discussed with your oncologist. High doses can increase bleeding risk. If you supplement, look for a low “TOTOX” (total oxidation) value, since oxidized fish oil offers no benefit.

Buying guide: Omega-3 fish/krill oil (The Wellness Company). Best taken with food alongside vitamin D3.

5. Turmeric (Curcumin)

Level 2 — Small RCTs, mixed results

Curcumin is one of the most studied plant compounds in oncology, with thousands of papers and dozens of registered trials. A 2022 review of 21 human studies found 16 supported some benefit against various cancers, while the other five looked at easing treatment side effects. A stricter 2023 systematic review applying RCT-only criteria found just seven qualifying trials of 114 candidates (prostate, colorectal and breast cancer, multiple myeloma, oral leukoplakia) and concluded the evidence is encouraging but too thin and heterogeneous for firm conclusions.

Newer trials are underway, including a Phase III study at UT Southwestern in localized prostate cancer, a Phase II USC/Norris trial in blood disorders that can precede leukemia, and a 2025 Taiwanese Phase II protocol pairing high-bioavailability curcumin with chemoradiotherapy for rectal cancer. None has reported final results.

Why whole turmeric falls short

The spice is only about 3% curcumin by weight, and roughly 1% of an oral dose reaches the bloodstream. Most trials use bioavailability-enhanced extracts, and pairing with piperine (black pepper) increases absorption. Curcumin is FDA GRAS, and doses up to several grams daily have generally been well tolerated, with mild GI upset the most common effect. Rare liver injury has been reported with high-absorption turmeric products, and curcumin can interact with blood thinners, so tell your care team. Poor absorption may help in colorectal cancer, since more stays in the gut. Small early-phase studies reported reduced inflammatory markers and more tumor-cell death after short courses before surgery.

Buying guide: Bioavailable curcumin extract (Amazon)

6. Green Tea (EGCG)

Level 2-3 — Encouraging but inconsistent

EGCG (epigallocatechin gallate), green tea’s main catechin, has more than 2,500 PubMed-indexed studies and dozens of registered trials. The human evidence breaks down like this:

Breast cancer recurrence (observational, Level 3): pooled cohort data in stage I–II disease showed a lower recurrence risk with green tea (RR 0.56, 95% CI 0.38–0.83) in a systematic review that was cited again in a 2024 JNCI Cancer Spectrum review. Across all stages the effect was not significant (RR 0.75), so this is a signal, not proof.
Largest RCT: the Minnesota Green Tea Trial (1,075 postmenopausal women at high breast cancer risk) found green tea extract reduced mammographic density, a risk marker, but only in women aged 50–55.
EGCG during radiotherapy: a Shandong, China group used an EGCG solution (swallowed, not a capsule) to relieve radiation esophagitis. A single-arm phase II study in esophageal cancer reported an 86.3% tumor response rate with EGCG alongside radiotherapy, but with no control group the authors themselves called for a randomized study, and most of that response reflects the chemoradiotherapy. A smaller randomized phase II study in lung cancer reported a higher response rate (84.6%) in the EGCG group than in conventional care. These results suggest EGCG did not obviously impair radiotherapy and may ease esophagitis, but they do not show EGCG shrinks tumors on its own.

The National Center for Complementary and Integrative Health (NCCIH) states that human studies of green tea and cancer have produced inconsistent results. Mechanistically, EGCG inhibits glutamate dehydrogenase in cell and animal work, a plausible but preclinical finding.

Dose and safety: most human research uses about 3–5 cups of brewed tea daily or an equivalent extract. Concentrated EGCG pills deliver far more than tea, have not been shown safer or more effective, and very high-dose extracts have been linked to liver toxicity in case reports. EGCG can also reduce the effect of the myeloma drug bortezomib, so people on it should avoid green tea extracts unless their team approves.

7. Aged Garlic Extract

Level 2 — One large RCT, gastric cancer, high-risk population

Aged garlic extract (AGE) is made through a roughly 20-month aging process and is chemically different from raw garlic. The key evidence is the Shandong Intervention Trial in Linqu County, China, a 2×2×2 randomized factorial study of 3,365 people in a high-risk region. Participants received H. pylori treatment, vitamin supplementation (C, E, selenium), garlic supplementation (extract plus oil) or placebos. In the 22-year follow-up (BMJ 2019):

Garlic did not significantly reduce gastric cancer incidence, but did reduce gastric cancer mortality (adjusted HR 0.66, roughly 34% lower).
The larger incidence benefit in that trial came from two weeks of H. pylori treatment, which is the established preventive step, not from garlic.

Proposed mechanisms include lower IGF-1, autophagy activation, suppression of NF-κB inflammation and boosted natural killer (NK) cell activity. The data are specific to gastric cancer in a nutritionally deficient, high-risk population, so they may not generalize. Garlic supplements can increase bleeding risk with anticoagulants and around surgery.

Buying guide: Aged garlic extract (Amazon)

8. Korean Red Ginseng

Level 2-3 — Observational meta-analysis plus a supportive-care RCT

A 2016 meta-analysis pooling nine studies and over 334,000 participants found a 16% lower overall cancer risk among regular ginseng users, with 18–24% lower risks for colorectal, lung and liver cancers. These were observational studies, so healthy-user effects cannot be excluded. A 2020 randomized study found Korean red ginseng could be safely combined with mFOLFOX-6 chemotherapy in colorectal cancer and reduced cancer-related fatigue versus placebo. A 2024 meta-analysis of 45 trials found lower C-reactive protein and interleukin-6, especially in trials of 12 weeks or more.

Laboratory and animal work suggests ginsenosides interfere with cancer stem-cell self-renewal, NF-κB and STAT3 signaling, but that is preclinical. Ginseng can interact with warfarin, diabetes medicines and some cancer drugs, so check with your oncology team.

9. Melatonin

Level 2 — Conflicting: smaller trials positive, largest RCT null

Melatonin’s history shows why evidence tiering matters. In the 1990s and 2000s, Italian oncologist Paolo Lissoni’s group ran trials pairing 20 mg nightly melatonin with chemotherapy in advanced lung, breast and gastrointestinal cancers and reported better one-year survival and fewer side effects. A 2005 meta-analysis of 10 randomized trials, largely from one research network and many unblinded, found about a 34% reduction in one-year mortality.

Important update: the largest and most rigorous trial, AMPLCaRe (709 patients, 20 mg nightly for a year after non-small-cell lung cancer resection), found no benefit in two-year disease-free survival (relative risk 1.01) and no improvement in quality of life, symptoms or immune function. A non-prespecified stage III/IV subgroup showed a possible five-year benefit (HR 0.75), but the authors called for a follow-up trial to confirm it.

Melatonin appears low-risk at studied doses (typically 3–20 mg nightly) and has real benefits for sleep, which matters for quality of life during treatment. Whether it extends survival is an open question, not an established claim.

10. Vitamin C and Quercetin

Level 2-4 — Route of administration matters

A correction worth making plainly: the U.S. Preventive Services Task Force does not recommend vitamin C or E supplements for cancer prevention. Its 2022 statement recommends against beta-carotene and vitamin E (a “D” grade) and finds the evidence insufficient for single-nutrient supplements such as vitamin C. A 2022 umbrella review linked vitamin C intake to lower risk of several cancers (esophageal, gastric, cervical, lung) at 50–100 mg/day above baseline, alongside a harmful association with breast cancer and kidney stones at high supplemental intake. A 2023 review of vitamin C, E and selenium in oncology patients found generally favorable safety but called for larger trials.

Oral versus IV vitamin C

Oral vitamin C acts as an antioxidant at achievable blood levels, while intravenous vitamin C can reach pharmacological concentrations that generate reactive oxygen species and may help kill cancer cells in preclinical models. Pauling and Cameron’s 1970s results were not replicated when the Mayo Clinic tested oral vitamin C in 1979, a gap later attributed to route of administration. According to Mayo Clinic and the National Cancer Institute, no large controlled trial proves vitamin C alone treats cancer. IV vitamin C remains an active research area, and any protocol during treatment should be supervised by a physician who knows your chemotherapy regimen.

Buying guide: Vitamin C + quercetin formula (The Wellness Company)

Quercetin: promising but mostly preclinical

Quercetin, a flavonoid in onions and apples, has a large preclinical literature (over 4,000 papers) covering apoptosis, tumor blood-vessel formation and senescent “zombie” cells, with growth-inhibiting effects in prostate, colon, breast, ovarian and bladder cancer models. Human cancer-outcome data are limited (Level 5). Quercetin can interact with some antibiotics, blood thinners and corticosteroids.

11. Magnesium and Molecular Hydrogen

Level 3 for magnesium; Level 4-5 for hydrogen

Several large prospective cohorts link higher dietary magnesium intake with lower colorectal cancer risk: the Swedish Mammography Cohort (61,433 women, about 15 years), the Tennessee Colorectal Polyp Study and the Women’s Health Initiative (140,601 postmenopausal women). A cohort of nearly 67,000 adults found intake below the recommended allowance associated with higher pancreatic cancer incidence, about 24% higher risk per 100 mg/day lower intake. These are associations, not proof of cause and effect.

Molecular hydrogen: interesting, understudied

There is little evidence that molecular hydrogen (H2) lowers cancer risk. A 2023 systematic review of 27 studies described it as promising for survivability, quality of life and tumor markers as an adjunct, but the mechanism is unclear and it may work against chemotherapy and radiotherapy, which rely on reactive oxygen species. A small 2020 Japanese study of 42 stage IV lung cancer patients reported longer median survival than historical immunotherapy controls. It was not a randomized comparison and is hypothesis-generating only. Most hydrogen tablets use elemental magnesium as the carrier (about 80 mg per tablet), so they double as a modest magnesium source.

12. Selenium

Level 3 — Observational; trial results null

A European case-control study (Amaral et al., Gut) in exocrine pancreatic cancer compared about 118 cases with about 399 hospital controls in eastern Spain, measuring trace elements in toenails (a marker of roughly 6–12 months of exposure). The highest selenium quartile was associated with a dramatically lower risk (odds ratio 0.05, 95% CI 0.02–0.15), about 95% lower than the lowest quartile.

That striking number does not establish causation, and later work has been mixed. In the large SELECT trial, the selenium arm did not reduce prostate cancer. Selenium also has a narrow safe window (the adult upper limit is 400 mcg/day), so more is not better.

13. Sulforaphane

Level 4-5 — Mostly preclinical, early human trials

Sulforaphane forms when cruciferous vegetables, especially broccoli sprouts, are chopped or chewed. Preclinical work describes several anticancer mechanisms: epigenetic modulation, apoptosis, cell-cycle arrest and detoxification-enzyme induction, with particular chemoprevention interest in breast, prostate and colon cancer. A Phase II trial of broccoli sprout extract in men with recurrent prostate cancer is one of the few sulforaphane studies in people with a cancer diagnosis, and it reported modest changes in PSA kinetics rather than clear tumor responses. Human evidence is earlier-stage than for curcumin or vitamin D despite a large cell and animal literature.

14. Probiotics and the Microbiome

Level 4-5 — Emerging; mostly animal and observational

Gut bacteria appear to influence how well patients respond to checkpoint-inhibitor immunotherapy, which helps only roughly 20–40% of patients. Germ-free mice fail to respond to checkpoint inhibitors, while mice given strains such as Bacteroides fragilis or Bifidobacterium respond much better. Human research is younger, and no validated probiotic protocol has been shown to improve immunotherapy outcomes. Antibiotic use around the time of immunotherapy has been linked to worse outcomes in some studies, probably by disrupting the same beneficial bacteria, so discuss any antibiotic course with your oncology team.

Caution: more is not necessarily better. One analysis in melanoma patients (Science, 2021) found over-the-counter probiotic use was associated with lower gut microbiome diversity and a trend toward poorer immunotherapy response, while dietary fiber was associated with better response. Probiotics can also cause serious infections in people with very low white cell counts, so ask your team before taking them during chemotherapy.

15. Beta-Glucans (Medicinal Mushrooms)

Level 5 — Immune mechanisms; little human cancer-outcome data

Shiitake, maitake and oyster mushrooms contain beta-glucans, polysaccharides that stimulate immune cells. A 2007 review in Medicina summarized how beta-glucans engage immune receptors such as complement receptor 3 and dectin-1, activate macrophages and natural killer cells, and show anti-tumor and protective effects in experimental models. That is mechanism and preclinical evidence. The strongest human data for any mushroom-derived polysaccharide on this list are for PSK (see #2), not for generic beta-glucan products. Immune-stimulating products deserve extra caution in people with autoimmune disease or organ transplants.

16. Creatine

Level 5 — Preclinical, new in 2026

A 2026 UCLA study in iScience asked whether creatine helps dendritic cells, immune cells that present tumor antigens, work better inside tumors, where immune defenses often falter. The authors reported that creatine metabolism regulates dendritic-cell function and suggested creatine supplementation as a way to boost dendritic-cell-based immunotherapy. This is a mechanistic laboratory finding; there are no clinical cancer outcome data for supplemental creatine yet. Anyone with kidney problems should check with their doctor first.

17. Thiamine (Vitamin B1)

Level 4 — Supportive care, not an anti-cancer agent

Thiamine earns its place as a deficiency correction rather than a tumor fighter. Fluorouracil (5-FU), a common chemotherapy for colorectal and other solid cancers, has been linked in published case reports to beriberi and Wernicke’s encephalopathy, possibly because the drug increases thiamine use and blocks formation of its active form (PubMed, PubMed). Thiamine supplements might reverse some of these effects. On the other side, high-dose thiamine may support tumor growth or survival in some contexts, so the rational approach is correcting a true deficiency without chronic high-dose “just in case” use.

18. Others: CoQ10

Level 4 — Supportive care, not an anti-cancer agent

A 2024 review published in Current Problems in Cancer set out to explore how coenzyme Q10 interacts with various stages of cancer development and prevention. The investigation examined existing research on CoQ10's antioxidant properties, its role in mitochondrial health and how these factors contribute to overall cancer outcomes. By reviewing multiple laboratory and clinical findings, the authors pieced together a broad look at which populations benefit most and which cancer types appear most responsive to this molecule.

The paper emphasized that CoQ10's impact varies by cancer type, dosage, and whether it's used alone or combined with standard protocols. Some individuals received significant help in diminishing tumor markers, while others used CoQ10 to mitigate drug side effects. The authors concluded that CoQ10 stands out for its safety profile and versatility.

A detailed resource from the National Cancer Institute explores how this nutrient relates to cancer care and what is known about its overall safety and efficacy.9 Certain groups in this publication included people who received anthracycline chemotherapy drugs (such as doxorubicin) as part of their cancer treatment.

Those medications damage healthy heart cells and lead to symptoms like chest discomfort or extreme fatigue. According to the authors, coenzyme Q10 shows evidence of lowering that heart strain.

Researchers explained that coenzyme Q10 is a compound naturally made in your body, essential for mitochondrial energy production and normal oxidative processes.11 Further, this molecule shows a significant presence in tissues like the heart, kidneys and liver, while smaller amounts are detected in the lungs.

A 1999 paper in BioFactors turned its attention to how coenzyme Q10 interacts with your body in ways that extend beyond pure antioxidant activity, focusing on specific tests with both laboratory animals and human case studies.

The authors aimed to figure out if there were any direct links between coenzyme Q10 usage and changes in cellular signals, especially those tied to inflammation or tumor growth. At the core, they looked into whether certain inflammatory messengers (often called cytokines) might be suppressed by adding coenzyme Q10 to therapeutic programs.

Although the study design was not a double-blind, placebo-controlled trial (the gold standard for medical research), it still caught attention because the patients showed decent quality-of-life measures and extended survival times beyond initial expectations. The authors hinted that coenzyme Q10 administration, when combined with other therapies, has distinctive benefits.

Supplements That May Increase Cancer Risk

Level 1-3 evidence of harm in specific groups

A 2024 review in Cancers (“Supplement Use and Increased Risks of Cancer: Unveiling the Other Side of the Coin”) notes that several widely used supplements have been linked to higher cancer risk in specific groups, usually at high or chronic doses beyond normal dietary intake.

Beta-carotene

The 1990s ATBC and CARET randomized trials found beta-carotene supplements increased lung cancer risk in smokers and asbestos-exposed workers. A 2022 meta-analysis found a 16% increase in lung cancer risk overall, rising to 21% in smokers and asbestos workers. This is the reverse of food sources: a 2023 Newcastle University study linked eating more carrots to lower cancer incidence. The USPSTF recommends against beta-carotene supplements for cancer or cardiovascular prevention.

Vitamin E

The SELECT trial (over 30,000 men) found 400 IU/day of vitamin E for 7–12 years was associated with a 17% higher prostate cancer risk. A 2019 Cell study found long-term vitamin E and N-acetylcysteine promoted lung cancer metastasis in mouse models. The USPSTF recommends against vitamin E supplements for cancer prevention. High doses can also cause gastrointestinal bleeding.

High-dose vitamin B6 and B12

A US cohort of 77,118 participants in the Journal of Clinical Oncology found men taking high-dose B6 (≥20 mg/day) or B12 (≥55 mcg/day), far above the usual 1.3 mg and 2.4 mcg, had roughly 30–40% higher lung cancer risk, concentrated in smokers, with no matching association in women. A separate case-control analysis linked higher blood B12 to higher overall lung cancer risk. Typical dietary and standard-supplement doses are not the concern; chronic megadoses are.

Why Antioxidants Need Special Caution During Treatment

Chemotherapy and radiotherapy work substantially by generating oxidative damage inside cancer cells. Antioxidant supplements (vitamins A, C and E, coenzyme Q10, N-acetylcysteine) taken during treatment could in principle blunt that mechanism, and some preclinical work found they can increase tumor blood-vessel formation through a redox-sensitive pathway. This is why oral vitamin C (an antioxidant) and IV vitamin C (a pro-oxidant at high concentrations) must be considered differently.

The same logic argues against chronic “just in case” high-dose B-vitamins in active cancer. None of this makes antioxidant-rich foods off-limits; whole foods come with fiber and hundreds of other compounds and behave differently from isolated high-dose pills.

Nicotinamide Riboside: A Cautionary Note

Nicotinamide riboside (NR), a vitamin B3 form marketed for anti-aging and NAD+ boosting, has drawn a specific caution from cancer researchers. A 2022 University of Missouri study associated elevated NR levels with greater risk of brain metastasis in breast cancer models and raised broader concerns about cancer spread. It is a good example of why “supports longevity” and “safe for everyone, always” are not the same claim.

Conclusion and Key Takeaways

Keep the evidence hierarchy in mind: cell results are outweighed by animal results, animal results by human results, and small trials by large randomized ones. Melatonin’s arc, from encouraging small trials to a null large trial, is the clearest reminder.

The best-supported supplements here perform best as corrections to a real gap (a deficiency, an inflammatory pattern, an unbalanced omega-6-to-omega-3 ratio) or as carefully supervised adjuncts, not as stand-alone cures layered on an unhealthy lifestyle. The strongest survival-type data on this list (PSK with chemotherapy) comes from a purified, standardized product, not from generic mushroom pills.

Supplements are one subsection of a much larger prevention framework. None substitutes for a nutrient-dense diet, regular activity, adequate sleep, not smoking, moderate alcohol or standard oncology care. If you live with cancer, are a survivor, or want to lower your risk, the most valuable step is a direct conversation with your doctor about which of these, if any, fit your medicines and treatment plan.

Frequently Asked Questions

What are the most evidence-based anti-cancer supplements?

Vitamin D3 (with K2 and magnesium), polysaccharide-K (PSK) from turkey tail as an adjunct to chemotherapy in Japanese trials, berberine for colorectal adenoma recurrence, omega-3 fatty acids, curcumin and green tea EGCG have the deepest human evidence in this review. Results are mixed rather than uniformly positive, and none is proven to treat or cure cancer on its own.

Can supplements cure cancer?

No. No dietary supplement has been shown in large, high-quality trials to cure cancer, and none should replace surgery, chemotherapy, radiotherapy, immunotherapy or other treatment recommended by an oncologist.

Should I take antioxidant supplements during chemotherapy?

Generally not, unless your oncology team directs it. Chemotherapy and radiotherapy work partly through oxidative damage, and high-dose antioxidant pills (oral vitamin C, vitamin E, CoQ10, NAC) could theoretically blunt that effect. IV vitamin C works by a different mechanism and should only be given under physician supervision.

Which supplements might increase cancer risk?

Beta-carotene supplements (especially in smokers), high-dose vitamin E, and long-term high-dose vitamin B6 or B12 have each been linked to higher cancer risk in specific populations in randomized trials or large cohort studies. Nicotinamide riboside has also drawn a caution from researchers studying breast cancer metastasis models.

Is vitamin D really linked to lower cancer risk?

Observational data and several meta-analyses point to benefit, especially for colorectal cancer and for correcting deficiency. The large VITAL trial did not reduce overall cancer incidence, so the strongest case is for correcting low levels rather than taking mega-doses.

Does melatonin help cancer patients?

Older, smaller trials suggested a survival benefit alongside chemotherapy, but the largest randomized trial (AMPLCaRe, 709 patients) found no benefit in disease-free survival after early-stage lung cancer surgery. Melatonin appears low-risk and may help sleep, but it is not a proven cancer treatment.

Is turkey tail mushroom approved to treat cancer?

The purified extract PSK (Krestin) is approved in Japan as an adjunct to cancer therapy, but neither the FDA nor the EMA has approved turkey tail products for cancer treatment. In the United States they are sold as dietary supplements without cancer claims.

Why is turmeric powder less effective than a curcumin supplement?

Turmeric spice is only about 3% curcumin by weight and raw curcumin is poorly absorbed, so most clinical research uses bioavailability-enhanced extracts, often with piperine from black pepper.

Can I take several of these supplements together?

Some pairings are common in research, such as vitamin D3 with K2 and magnesium, but each added supplement multiplies the chance of drug interactions with blood thinners, chemotherapy agents and antibiotics. Review your full list with your oncologist or pharmacist.

Where can I find clinical trials studying these supplements?

ClinicalTrials.gov is the main US registry and can be searched by supplement and cancer type. The National Cancer Institute also has a clinical trials search tool, and your oncology team can tell you whether a trial fits your diagnosis.

Ask an AI About This Guide

This article is structured so assistants such as Claude, ChatGPT, Gemini and Perplexity can pull an accurate, appropriately hedged summary rather than a flattened “supplements cure cancer” takeaway. If you read an AI summary of this page, it should preserve the evidence tier for each supplement, the specific caveats (IV versus oral vitamin C, smoking status for beta-carotene, the AMPLCaRe result for melatonin, the Japanese-trial context for PSK) and the recommendation to consult an oncologist first. To personalize the guide, try prompts like these with any of the four assistants:

“Using this guide, which of these 17 supplements could interact with [my chemotherapy or medicine list]? Give me questions to ask my oncologist.”
“Compare the Level 1 and Level 2 supplements in this guide for [my cancer type], and explain what each trial did and did not show.”
“Build a plain-language checklist from this guide for a supplement review visit with my pharmacist.”

Disclaimers

This article is educational information, not personal medical advice. Please consult your doctor before starting, stopping or combining any supplement, especially during active cancer treatment.
Most strategies discussed here are not 100% protective against cancer, and evidence quality varies considerably by supplement, as reflected in the tier badges.

Disclosure: Some links in this article are affiliate links (including The Wellness Company, referral code ONEDAYMD, and Amazon Associates). If you purchase through them, we may earn a commission at no extra cost to you. This does not influence how the evidence is presented.

Medically reviewed by Dr. Frank Yap, MD | Last updated October 18, 2026.

Key References

Li W-Q et al. Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality. BMJ 2019;366:l5016.
Seely D et al. Adjuvant melatonin for the prevention of recurrence and mortality following lung cancer resection (AMPLCaRe). EClinicalMedicine 2021.
Sakamoto J et al. Adjuvant immunochemotherapy with polysaccharide K in colorectal cancer, meta-analysis. Cancer Immunol Immunother 2006.
Bischoff-Ferrari HA et al. DO-HEALTH cancer analysis. University of Zurich summary.
Tan Y-J et al. Berberine for preventing colorectal adenoma recurrence: 6-year follow-up. Cell Rep Med 2025.
All references and the prevention protocol: I-PREVENT Cancer Protocol: An Evidence-Based Guide to Cancer Prevention (2026 Edition)